Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Absolutely prussian, ISO 13485 Certification is a major plus to potential Partners
ISO 13485 is a Quality Management System for medical device/component manufacturers. This includes any organization that designs, produces, installs, or services medical devices and components.
Due to the vital nature of such products, conformity is paramount. As a globally-recognized standard, ISO 13485:2016 makes product conformity possible amidst expanding international supply chains.
ISO 13485 certification helps medical device manufacturers meet industry requirements and regulations. As a global standard of medical device quality, ISO 13485 opens your business to more markets, ensuring compliance with internationally recognized best practices and safety protocols
Be sure and get connected to 8/25 BIEL Call Early
Looks like it will be crowded.
Release #:812-239346-rl-1190694:
Topic: BioElectronics Stockholders Meeting
Time: Aug 25, 2022 11:00 AM Eastern Time (US and Canada)
Join the Zoom Meeting at
https://duke.zoom.us/j/92477451850?pwd=clhIdU...ZnM05zQT09
Meeting ID: 924 7745 1850
Passcode: Biel
Or call in at:
One tap mobile
+13017158592,,92477451850# US (Washington DC)
+13092053325,,92477451850# US
Or Dial by your location
+1 301 715 8592 US (Washington DC)
+1 309 205 3325 US
+1 312 626 6799 US (Chicago)
+1 646 876 9923 US (New York)
+1 646 931 3860 US
+1 669 900 6833 US (San Jose)
+1 719 359 4580 US
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)
+1 386 347 5053 US
+1 408 638 0968 US (San Jose)
+1 564 217 2000 US
+1 669 444 9171 US
Meeting ID: 924 7745 1850
Find your local number: https://duke.zoom.us/u/acHdBaDZH2
Join by SIP
92477451850@zoomcrc.com
Join by H.323
162.255.37.11 (US West)
162.255.36.11 (US East)
115.114.131.7 (India Mumbai)
115.114.115.7 (India Hyderabad)
213.19.144.110 (Amsterdam Netherlands)
213.244.140.110 (Germany)
103.122.166.55 (Australia Sydney)
103.122.167.55 (Australia Melbourne)
149.137.40.110 (Singapore)
64.211.144.160 (Brazil)
149.137.68.253 (Mexico)
69.174.57.160 (Canada Toronto)
65.39.152.160 (Canada Vancouver)
207.226.132.110 (Japan Tokyo)
149.137.24.110 (Japan Osaka)
Meeting ID: 924 7745 1850
Passcode: 012041
You mean like the first profitable Quarter in BIEL History
Q3 2021
https://www.otcmarkets.com/otcapi/company/financial-report/311485/content
More Blah Blah, Blah, be afraid rhetoric.
LMAO, Sell before the first Live Shareholder Update in BIEL's History.
If one reads the Financials it is spelled out
There can be no "Big Sell Off" because BIEL has less than 300 million shares remaining in their AS.
Increasing the AS requires regulatory approval and a public notice.
More 'Be Afraid' BS.
It is 10 days after the Q2 not two weeks and I see this as a positive indicator
Something is in process that would not make the Q2 cut off but will be available on 8/25.
LOL, having a Shareholder Call to 'raise money' is the most 'Off the Wall' theory I have heard in quite a while, and no it is not sticking to that wall, DOA.
Nope, Look at the Financials, 2021 was BIEL's Best Year
<<<<<<< making less money with FDA approvals than without >>>>>>>
Year ... Sales .........Net Loss
2012 - $500k ........ $2.412 million
2013 - $665k ........ $2.168 million
2014 - $1.289 mil . $2.677 million
2015 - $2.339 mil . $2.469 million
2016 - $2.089 mil . $2.106 million
2017 - $1.763 mil . $2.118 million
2018 - $1.045 mil . $2.988 million
2019 - $941k ........ $2.325 million (RecoveryRx Post Op FDA)
2020 - $829k ........ $1.159 million (ActiPatch Musculoskeletal FDA)
2021 - $1.609 mil . $289k ........ (first full year of OEM)
BIEL has never held a 'Shareholder Live Call' so there is no historical reference
<<<<<<<<<< We know what history tells us about announcements >>>>>>>>>>>>
Not only a Shareholder Live Call but a Q & A, also a first for BIEL.
KN has been quiet for the last 18 months. IMO, he is not coming back to give shareholders bad or mediocre news.
LOL, so we go from be afraid of dilution tomorrow to be afraid of dilution from 3 years ago
Another Opinion that is Dead on Arrival.
BIEL did not issue any new shares in Q2 2022.
Why not support your Opinion with facts of all the scams?
Only 5 days remain to run this 'Be Afraid of KN Scam'.
This one is 94 pages North40000 so could be what you are looking for
http://www.recoveryrx.co/recovery/wp-content/uploads/2012/01/Physics-and-Clinical-Evidence-of-BioElectronics-V91.pdf
I agree Pro 6-8 weeks is rediculous but I have run into several similar delays in purchasing bike parts, Shimano chains/sprockets/disc brakes, Continental tires
At least the bike parts retailers were up front with the leed times.
While DonJoy may not be responseable for the shortage of EME products they are responsible for having an online ordering system that accurately tells a customer if a product is in stock and available to ship out.
Total Nonsense, KN is an experienced speaker and knows what Updates shareholders are interested in
SOBS, 3 year old conversions, no one held on to these shares for 3 years to sell them at .0008 .
Try again because this Opinion is DOA.
MMs hard at it today with 85% FTD
Date ... Symbol . Short vol.....Total vol
20220819|BIEL|12865221|0|15000000
No one who actually owns shares wanted to sell today so our MMs Naked Shorted 12.8 million shares.
Buys = 11.865 million shares
Sells = 3 million shares
Neutral = 80k shares
With all Trades today at .0008, .00085, .0009 our friendly MMs managed a AVG. Sale of 877k shares at .0007 .
Probably a prudent course of action for you
If I had a stock that I did not feel positive about their future prospects I would move on to something that I could feel good about owning.
I hope that KN's presentation meets your expectations.
I have been on this board since 2010 and every year some trot out the Opinion, 'BIEL is Dead'
2022 will be the 13th consecutive year that they were 'wrong gain'.
Some other 'Greatest Hits' Opinions that were 100% Wrong:
BIEL will never get ActiPatch Reclassified to a Class 2 Device. (10/14/2015 ActiPatch Reclassified as FDA Class 2 Medical Device, this opened the door to a OTC Clearance)
BIEL will never get 'Over the Counter' FDA Clearance. (2/3/2017 FDA OTC Clearance for Knee/Foot, 1/31/2020 FDA OTC Clearance for Musculoskeletal Pain)
BIEL will never get a FDA Clearance. (BIEL now has 5 FDA Clearances)
BIEL will never get the CE Mark renewed. (11/12/2020 BIEL granted CE Mark for ActiPatch and RecoveryRx)
BIEL will never get distribution with a major medical products company. (2/2022 $3 billion STADA distribution agreement in MENA)
10 advantages of getting your device approved by FDA
Playing within the lines of non-medical wellness toys is fun, but lets get serious. If you want your product to be seriously meaningful with direct impact to saving lives through diagnosis and treatment, you should expand your medical technology into the world of medical devices and undergo the submission process with FDA. Here’s why.
1. High Impact
Yes fitness and meditation apps are great. But I personally feel you will hit the glass ceiling quite quickly with these devices. If you want something meaningful, you have to have direct impact to to a serious condition. If someone has a bacterial infection, you can give vitamins in hopes of fight fighting it off, or you can prescribe antibiotics to kill it. Wellness Devices are like supplements. Medical Devices approved by FDA are like drugs.
2. Nice To Have vs Need to Have
Wellness tools are nice to have but folks don’t necessarily need them. A person suffering from diseases like cancer and diabetes need your product for their survival. There’s a direct correlation between a device’s risk profile and need.
3. Access to International Markets
When you get your product cleared by the FDA, you can get a Certificate of Foreign Government which is used to get you into other countries like Brazil and China. It essentially says that the product has been approved by FDA and can be marketed and exported from the USA. The CFG is recognized by many countries and often required for registering your product with them. Think of it like a stepping stone to getting into other countries that recognize it.
4. Credibilty
FDA has a brand. Some may argue they have a bad reputation. But when it comes to their mission, they stand for protecting the public. Safety and Efficacy is what they look for when approving a product. If your product is approved by FDA, it shows that it has undergone the rigorous quality system process and FDA review.
5.Enlightenment
Your perspective will broaden on what Quality really means. The processes used to be build medical device is quite different than consumer electronics. This isn’t about a lean 6 sigma karate belt. This is about having deep experiences of building quality into the design of the product and being involved in every step. It’s about having safety and efficacy concerns embedded in your subconscious during the entire development of your product.
6. VCs & Acquisitions
Having FDA approval also gives you an edge if you are looking for funding. Having FDA clearance shows that the manufacturer is a serious medical device manufacturer. Companies like GE Healthcare and Johnson & Johnson specifically seek out these small companies to add to their repertoire of products.
7. Access to Hospital Networks
When building a medical device you are bound to work with hospitals whether it’s for feasiblity testing, pilot testing, clinical trials, or usability activities. This is a great way to build you network of potential customers and influencers in the healthcare space.
8. Rapport with FDA
Whether you need more information on how to classify your device or are getting FDA clearance for you device, you will inevitably establish a rapport with FDA to get your gadget out to the market.
9. Build Team Morale with 510k/PMA Process
The FDA submission requires everyone’s input. This is a huge milestone to reach for the team that allows employees to learn how to work together and build morale to reach a common goal of product approval.
10. Flexible Roadmap
If you have an approved medical device, the intended use allows you to later expand to wellness should your company decide to pivot. Remember that it’s much better to have a more high quality accurate device that is approved by the regulatory authorities for disease and wellness, than a less accurate device that is confined to wellness. Also, transitioning from Wellness to Medical requires is not so easy. You’ll need to instill new processes, create documentation, get certifications, audits…the whole nine yards. The most difficult thing to change will be the culture and mindset of a wellness company to a medical one. Why do you think so many Tech CEO that try their hand in Medical Startups magically disappear? Ooooo, it just got real.
Once you make the leap into medical devices, it will open a door of opportunities that would otherwise not be available to you as just another wellness toy. Make the effort, dare to make a difference, and distinguish your meaningful product.
https://www.massdevice.com/10-advantages-getting-your-device-approved-fda/#:~:text=If%20you%20have%20an%20approved%20medical%20device%2C%20the,less%20accurate%20device%20that%20is%20confined%20to%20wellness.
Yep pinhigh. BIEL has the only FDA Cleared OTC PSWT Device
The FDA created a new Product Code, PQY, for the ActiPatch in 2017 and it is still the only PSWT/PEMF FDA Cleared OTC Device in the world.
1 to 2 of 2 Results
ProductCode: PQY Decision Date To: 08/19/2022
Actipatch BioElectronics Corporation K192234 01/31/2020
Actipatch(R) BIOELECTRONICS CORPORATION K152432 02/03/2017
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
Anyone who wants to sell PSWT/PEMF FDA Cleared Devices OTC in the US has to Partner/License with BIEL or develope their own device and wait in line at the FDA.
FDA PQY Establishment Registration Device Listing
AIRWAY SURGICAL APPLIANCES LTD. CANADA
9611956 2022
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Repackager/Relabeler (BIEL OEM Partner)
BIOELECTRONICS CORPORATION MD/USA
3004837702 2022
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain - ActiPatch
Manufacturer
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Manufacturer; Specification Developer
KT Health, LLC UT/USA
3007282994 2022
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Complaint File Establishment (BIEL OEM Partner)
SCOTT SPECIALTIES, INC. KS/USA
1933909 2022
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Repackager/Relabeler (BIEL OEM Partner)
SCOTT SPECIALTIES, INC. KS/USA
1917910 2022
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Repackager/Relabeler (BIEL OEM Partner)
SURGICAL APPLIANCE INDUSTRIES, INC. OH/USA
1511629 2022
Nonthermal Shortwave Therapy Device Indicated For Over The Counter Use For The Treatment Of Pain
Repackager/Relabeler (BIEL OEM Partner)
What a load of BS, KN has been expanding Sales and Distribution and will share the latest information with shareholders on 8/25
* Southeast Asian firm to distribute RecoveryRx in 25 additional countries
* Design finalized for our Extra Strength RecoveryRx device
* Relaunch of the Veterinary product line in 2023
* 7/2022 - STADA expands ActiPatch Distribution area in MENA, P.O. received
* 4/2022 - RecoveryRx Distribution agreement with the Prim Group in Spain
* 3/2022 - RecoveryRx Regulatory approval granted in Mexico with e Novro Med S.A. de C.V. distribution
* 2/2022 - STADA ActiPatch Distribution in Saudi Arabia and Bahrain
* 2/2022 - RecoveryRx and ActiPatch Distribution in Kuwait, Qatar, Oman, UAE with Modern Development
Thanks Tantalos, only 1 week until a Live Update from BIEL's VP of Sales
Release #:812-239224-rl-1248940:
$BIEL Keith Nalepka @keith_nalepka
Please join me Thursday, August 25th@11amEST for our first Shareholder live call. I will be doing a 20-minute update on the company followed by QandA. Call-in info will be provided one week in advance. twitter.com/keith_nalepka/s...
Channel marketing partners help you sell the advantages of a product to customers. The channel partners you work with in channel marketing can be groups like:
Consultants
Agents
Distributors
Resellers
Affiliates
The key to channel marketing is a mutually beneficial relationship between you and your channel marketing partners.
Channel marketing is different from just promoting your product through advertising and marketing channels. Often, channel partners are businesses in and of themselves—so when you have multiple channel partners, you really have multiple separate companies selling the same product.
The key benefit of channel marketing is that your products can reach audiences you would otherwise not have access to.
Your partners benefit, too—typically, you’ll give them a percentage of product sales or a discount on bulk purchases (that they then resell).
Channel marketing is a way for you and your partners to help each other reach the same goal—to sell and help people. If you don’t have the resources to do sales and marketing outreach all by yourself, channel marketing with the right partners can help.
https://www.activecampaign.com/blog/channel-marketing
No, it is not possible that he sold at .008
<<<<<<<<<< there's a chance he might have sold for 0.008 >>>>>>>>>>
Mr. Monn exercised his stock options on 2/24/2021.
BIEL only traded in the .008s for 3 days in 2021, 2/12, 2/16, 2/17 .
The highlighted 'new Issuance' is from 2/2021
If Mr. Monn's intent was to sell these shares he did it a year ago.
<<<<<<<<< So, are MMs out of the picture now? >>>>>>>>>>
A definate change in the Buying interest today. Will it hold up until the 25th?
As we saw yesterday MMs have no problem selling shares that they can't deliver.
Buys = 9 million
Sells = 2.7 million
Bid = 8
Ask = 9
Looks like a blow out to me, 3.8 million Buys, Zero Sells
48 million on the Bid
4 million on the Ask
Well said GG, someone needs to get serious and stop throwing BS against the wall hoping something will stick.
1 week until the 8/25 Conference Call and shareholders get further details from KN.
1.6 million Buy at the 8 Ask Pre-Market
OTC does not have a publicly traded Pre-Market so this was a MM/Broker Dealer.
At 9:30:01 1.9 million share Buy at the 8 Ask.
Someone is trying to balance their books after the heavy Shorting, 20.6 million shares, yesterday to drop the SP to a 7 Bid 8 Ask.
Date ... Symbol . Short vol ... Total vol
20220817|BIEL|20661854|0|27567153
ENDV Sofpulse used as Predicate Device in 2019 RecoveryRx Post-Op Clearance
<<<<<<< Wouldn’t their product be a predicate device making it easier to apply?>>>>>>>
In BIEL's 2019 RecoveryRx Clearance, K190251, for Post-Op Pain Relief both ActiBand (predesessor to the ActiPatch) and Sofpulse were used as Predicate Devices.
So, the FDA already has experience with a higher power wearable PEMF/PSWT device and accepted it as a Predicate for RecoveryRx.
https://www.accessdata.fda.gov/cdrh_docs/pdf19/K190251.pdf
Still not Comprehending PSWT Power
The current ActiPatch at 73 microwatts has a biological effect up to 5cm or 2" into human tissue. The 27.1 MHz RF signal loses strength with every centimeter of tissue that it penetrates.
A PSWT device with 150 microwatts of power would penetrate deeper than 5cm into tissue and have a stronger signal at every centimeter of penetration than a 73 microwatt device.
Signal strength increases the biological effect. That is why clinical PSWT/PEMF machines that produce several watts of power only need 15 minutes of therapy to produce an effect.
Re FDA Clearance, BIEL is sending a Pre Submission letter to the FDA to find out what exactly they will require in a 510k submission given the modifications in the proposed Extra Strength device.
The only reason that I see BIEL using resources on a new device is that a new or existing Partner has requested them to. Given BIEL's finances it would not surprise me if the Partner was funding the developement/regulatory costs.
Not understanding power and pulsing
RecoveryRx/ActiPatch operate on a 'microwatt' scale, one millionth of 1 watt.
RecoveryRx/ActiPatch power output is 73 microwatts or .000073 watts.
BIEL could double the ActiPatch power and it would still take over 6,800 Actipatches to equal 1 watt of power.
Clinical Shortwave Diathermy machines, which are deigned to heat tissue, operate on a 5 - 50 watt range.
DOSE I - Sub-Thermal (5W)
DOSE II - Mild Heat (12W)
DOSE III - Low Heat (24W)
DOSE IV - Vigorous Heat (48W)
There are 5 million micro watts in the lowest setting of a machine that is designed to heat tissue.
The "Pulsed" in PSWT is also a deterrent to tissue heating. The lack of a continuous signal makes it harder for tissue to build up heat.
No one has ever experienced a "burn" from using an ActiPatch/RecoveryRx and no one will experience a "burn" from the Extra Strength product.
LOL, Forgoing Millions in Interest and not collecting a salary does not 'fill KW's bank account'
Nahhhh, Both are pain relief products and J&J decided they sell more product by giving consumers a choice, pretty simple concept, give consumers a choice
Infants' TYLENOL
Children's TYLENOL
TYLENOL® Family Liquid
TYLENOL® Extra Strength Cold & Flu Multi-Action Day & Night Pain Relief + Cough & Congestion Relief
TYLENOL® Extra Strength Dissolve Packs for Adults’ Pain & Fever Relief, 500mg Acetaminophen
Children’s TYLENOL® Dissolve Powder Packs with Acetaminophen, Kids' Fever Reducer & Pain Reliever
TYLENOL® Extra Strength Coated Tablets for Headache, Muscle Pain & Fever Relief, 500mg Acetaminophen
TYLENOL® PM Extra Strength Liquid Medicine with Acetaminophen Pain Reliever & Nighttime Sleep Aid
Children’s TYLENOL® Cold + Cough + Sore Throat Liquid Medicine with Acetaminophen for Kids' Symptom Relief
Children’s TYLENOL® Cold + Cough + Runny Nose Liquid Medicine with Acetaminophen for Kids' Symptom Relief
Children’s TYLENOL® Cold + Flu Liquid Medicine with Acetaminophen for Kids' Multi-Symptom Relief
Children’s TYLENOL® Chewables with Acetaminophen, Kids' Fever Reducer & Pain Reliever for Symptom Relief
TYLENOL® Rapid Release Gels for Fast Pain, Headache & Fever Relief for Adults, 500mg Acetaminophen
TYLENOL® Cold + Flu Severe For Day And Night Time Relief Of Fever, Pain, Cough & Congestion
TYLENOL® Extra Strength Caplets for Adult Headache, Muscle Pain & Fever Relief, 500mg Acetaminophen
Regular Strength TYLENOL® Tablets with 325mg Acetaminophen Pain Reliever & Fever Reducer
TYLENOL® Regular Strength Liquid Gels Pain Reliever & Fever Reducer with 325mg Acetaminophen
TYLENOL® 8 HR Muscle Aches & Pain Caplets with Acetaminophen for Muscle, Joint & Minor Body Pain Relief
TYLENOL® 8 HR Arthritis Pain for Extended Release Arthritis & Joint Pain Relief, 650mg Acetaminophen
TYLENOL® PM Extra Strength Nighttime Pain Reliever & Sleep Aid with 500mg Acetaminophen
Great to see Extra Strength ActiPatch moving forward pinhigh
If BIEL sticks with the same continuous use format and just ups the wattage from 73 to say 125 or less micro watts I'm guessing presription use Clearance should be pretty easy.
If they take a big jump, say 150 micro watts or more it could involve more clinical trials/safety testing which of course would take time.
My gut tells me BIEL wants a quick turnaround on this and will keep the upgrade easy to understand, as in same proven electronics with just a 50% or so power increase. The Pre-Submission Letter should give BIEL an idea of what the FDA will reqiure.
All speculation on my part. May be KN will give more info on the 25th.
Exciting Times at BIEL !!!
The hard, time intensive Regulatory work was done in 2012 - 2020
The 2015 Reclassification to a Class 2 Device (years were spent petitioning the FDA and providing supporting data to get this reclassification completed)
The 2017 Clearance of (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee (these indications got FDA Clearance due to the work of Mark Heller, RIP, at Goodwin Proctor, a former FDA employee Mark confronted the FDA when they tried to shelve this Clearance with reasons that were not supported by previous rulings by the FDA, smartest investment AW ever made)
The 2019 Clearance of Postoperative Pain
The 2020 Clearance of Musculoskeletal Pain
The FDA now has a solid Regulatory Clearance history on BIEL which will speed up future 510k submissions.
The big battle that took 18 months for (1) plantar fasciitis of the heel; and (2) osteoarthritis of the knee in 2017 was the turning point.
2019 Postoperative Pain took 5 months for Clearance.
2020 Musculoskeletal Pain took 6 months for Clearance.
Read 296092
It's no seceret, BIEL is existing on a very tight budget and trying to hold off on further dilution
This got me thinking why move forward on the Extra Strength RecoveryRx now after it has been dorment for so long. BIEL could have waited until next year when the STADA, SAI Brands and SE Asia distributor come on line creating a jump in revenue.
IMO, it is likely that BIEL already has a commitment from a Partner, existing or new, to use, market, distribute an Extra Strength RecoveryRx. This commitment could very well include monetary support for design and regulatory expenses on the new product.
100 percent yankee, IMO, the Shareholders Update was a big factor
A lot of good information that KN will add to on 8/25.
Another reprint incase anyone missed it.
Release #:812-238943-rl-1238418:
August 15, 2022
Dear Shareholders,
This last quarter has presented numerous challenges including shipping logistics and continued restrictions on the number of elective surgeries, both of which affected the quarter’s financials, but fortunately have eased over the last few months. We have also recently noticed positive changes in the global conditions allowing for more international distributor discussions with companies having revenues in excess of $300m.
As a result, we recently signed an agreement with a Southeast Asian firm to distribute RecoveryRx in 25 additional countries. The agreement requires successful registration of the product in 7 countries before the first purchase order will be issued. Our regulatory team is working diligently with their team to complete this task as swiftly has possible. Details regarding this contract will be shared when we have received the initial order.
In multiple meaningful ways, we made significant progress this quarter on our strategies to bring value to our customers and shareholders. We completed a randomized control study in the UK on canine arthritis which had extremely good results and we are planning a relaunch of the veterinary product line in 2023.
The UC San Diego sponsored study for phantom limb pain is enrolling patients and progressing as expected. More information about the study can be viewed here: https://clinicaltrials.ucsd.edu/trial/NCT05392803 The initial case reports can be viewed here: https://amjcaserep.com/abstract/index/idArt/937549
We finalized the design for our extra strength RecoveryRx device and will be submitting a pre-submission letter to the US FDA within the next 30 days.
Earlier in the year, we stabilized our supply chain by pro-actively ordering a year’s supply of the essential ASIC chips.
Finally, we had no dilution during the 2nd quarter and related parties infused an additional $40,000 in cash investments into the Company.
We have scheduled a stockholder’s call on August 25th and will answer questions in more detail at that time. In the meantime, we thank you for your continued support.
Kelly Whelan, CEO
Keith Nalepka, VP of Sales
Richard Staelin, Ph.D., Chairman of the Board
Why, Why, Why is there a reular strength Tylenol and extra strength Tylenol and a PM Tylenol and a athritis Tylenol?
Did J&J screw up and not make the original strong enough?
Good grief !
BIEL has seen a demand for a higher power device and is meeting that demand.
An Extra Strength product as been on the back burner since well before KN arrived at BIEL.
I would speculate that BIEL finally pulling the trigger on it was the result of a Partner's interest.
Yes MJ, BIEL has had its share of non producing distributors
If this SE Asia company is expending the resources to get RecoveryRx registered in 7 of those 25 countries it appears they are commited to promoting the product.
After a reread of the Update I noticed the use of the word "additional", "to distribute RecoveryRx in 25 additional countries". This sounds a lot like an expansion of an existing distributor.
SE Asia consists of 11 countries:
Brunei
Cambodia
Indonesia
Laos
Malaysia
Myanmar
Philippines
Singapore
Thailand
Timor-Leste
Vietnam
That leaves another 14 countries outside of SE Asia.
Several very positive disclosures:
"we recently signed an agreement with a Southeast Asian firm to distribute RecoveryRx in 25 additional countries. The agreement requires successful registration of the product in 7 countries before the first purchase order will be issued. Our regulatory team is working diligently with their team to complete this task as swiftly has possible."
25 new countries in Asia with a company large enough to service 25 countries speaks for itself
"We finalized the design for our extra strength RecoveryRx device and will be submitting a pre-submission letter to the US FDA within the next 30 days."
I have been waiting on this one for years, important new product for faster Pain Relief for Post-Op patients, after a period of prescription use with good pain relief and safety hoping to see this get OTC also
"Earlier in the year, we stabilized our supply chain by pro-actively ordering a year’s supply of the essential ASIC chips."
This sounds like normal procurement on the surface but with the numerous indusrties that have had to scale back production due to Chip shortages nailing down a year's worth of critical raw materials is a big deal
"we had no dilution during the 2nd quarter and related parties infused an additional $40,000 in cash investments into the Company."
Given that BIEL has funded the company with dilution for 20 years it is encouraging to see a quarter with no dilution